TransCode Therapeutics Inc (NASDAQ:RNAZ) shares, rose in value on Wednesday, April 16, with the stock price down by -10.40% to the previous day’s close as strong demand from buyers drove the stock to $0.36.
Actively observing the price movement in the last trading, the stock closed the session at $0.40, falling within a range of $0.3528 and $0.395. The value of beta (5-year monthly) was 1.519. Referring to stock’s 52-week performance, its high was $66.33, and the low was $0.34. On the whole, RNAZ has fluctuated by -56.23% over the past month.
With the market capitalization of TransCode Therapeutics Inc currently standing at about $8.32 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Apr-14.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that RNAZ’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of RNAZ currently trading nearly -32.35% and -89.41% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 27.25, while the 7-day volatility ratio is showing 14.10% which for the 30-day chart, stands at 21.34%. Furthermore, TransCode Therapeutics Inc (RNAZ)’s beta value is 1.53, and its average true range (ATR) is 0.27.
A comparison of TransCode Therapeutics Inc (RNAZ) with its peers suggests the former has fared considerably weaker in the market. RNAZ showed an intraday change of -10.40% in last session, and over the past year, it shrunk by -97.99%%.
Data on historical trading for TransCode Therapeutics Inc (NASDAQ:RNAZ) indicates that the trading volumes over the past 10 days have averaged 2.07 and over the past 3 months, they’ve averaged 7.41 million. According to company’s latest data on outstanding shares, there are 23.34 million shares outstanding.
Nearly 10.11% of TransCode Therapeutics Inc’s shares belong to company insiders and institutional investors own 0.78% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 2.55 million shares as on 2025-03-31, resulting in a short ratio of 0.17. According to the data, the short interest in TransCode Therapeutics Inc (RNAZ) stood at 36689.00 of shares outstanding as of 2025-03-31; the number of short shares registered in 2025-02-28 reached 0.54 million. The stock has fallen by -89.42% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the RNAZ stock heading into the next quarter.
